Title: Johnson & Johnson (NYSE:JNJ) Increases Dividend and Reports Strong Q1 Earnings Growth
Date: 2025-04-15 17:30
URL: https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-increases-173039383.html?.tsrc=rss

Oops, something went wrong Tip: Try a valid symbol or a specific company name for relevant results Oops, something went wrong Why your water bill is an inflation problem that isn't budging Stock market today: Dow, S&P 500, Nasdaq futures fall as Nvidia reveals costly limits on China exports The Treasury secretary told Yahoo Finance that the next 90 days should provide 'substantial clarity' on tariffs Treasury Secretary Scott Bessent tells Yahoo Finance that the US has a 'big toolkit' to deal with bond market volatility Stocks drift lower as tariff chaos pauses for a day The chip giant committed to building AI infrastructure in the US, and Trump says he's going to help make it happen. The fallout from Trump's tariff whiplash hasn't yet pushed investors to shy away from an old habit Stocks edge higher after back-to-back rallies with Trump's latest tariff moves in focus BofA's Moynihan says 'we potentially face a changing economy' after highest-ever equities trading haul The trade war uncovers new economies of scale Trump is wrecking his own economic agenda Higher clothing costs from tariffs are coming soon — but not immediately, experts say Why Tesla, GM, and Rivian will be hurt most by China's critical minerals export ban Trump says he's 'looking at something' to help car companies with tariffs Stocks rally for second straight day, while Apple jumps on tech tariff reprieve The Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon trading Americans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey found Stocks surge as Apple leads way higher after tech's tariff reprieve Trump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bend Goldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slows Corporate earnings take center stage amid tariff turmoil: What to know this week Trump has tariffs, taxes, and the debt ceiling on a collision course for this summer Trump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg) Tax day 2025 is coming up. Here’s what to know to file by the deadline. Commentary: Put the P/E ratio in timeout for now Market chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landing Apple was on brink of crisis before tariff concession from Trump (Bloomberg) Corporate earnings take center stage amid tariff turmoil: What to know this week The best (and worst) time of year to buy a house The Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg) How to invest in gold in 4 steps Changing jobs can disrupt saving for retirement. Here's how to stay on track. Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg) Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard of The tariff uncertainty isn't getting any better in markets: Chart of the Week 'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflation Gold notches best week since 2020 amid 'shaken' investor confidence in US The bond market just had one of its most volatile and unusual weeks in recent memory Stocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023 Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains. The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market. Consumer sentiment craters further as inflation expectations soar to highest since 1981 Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll in JPMorgan's Dimon says economy is facing 'considerable turbulence' Tariff uncertainty muddies — and refocuses — earnings season China raises tariffs on US goods to 125% from the 84% planned in response to Trump's latest hike China already knows Trump's breaking point in their burgeoning trade war, our columnist writes How the bond market helped make Trump blink on tariffs The Dow fell 1,000 points, and the S&P 500 and Nasdaq were crushed as stocks resumed a tariff-fueled sell-off Trump's total tariff on China is actually 145%, the White House said, an amount higher than the 125% previously reported Unlock stock picks and a broker-level newsfeed that powers Wall Street. Johnson & Johnson recently announced a 4.8% increase in its quarterly dividend and released positive Phase 3 clinical data for icotrokinra, an oral treatment for plaque psoriasis. These events occurred alongside solid earnings reports, with a significant rise in net income and earnings per share compared to the previous year. While the company's stock price increased by 6.64% over the last quarter, the broader market also trended upward, climbing 5.9% in the past year. These company developments likely complemented the overall market movements and investor sentiment, rather than diverging from broader trends. You should learn about the 1 warning sign we've spotted with Johnson & Johnson. Outshine the giants: these 25 early-stage AI stocks could fund your retirement. Johnson & Johnson's recent dividend increase and positive Phase 3 clinical data for icotrokinra could significantly bolster investor confidence by enhancing perceptions of future earnings potential and revenue growth. The company's total return, including dividends, was 17.11% over the past five years, indicating steady but moderate financial performance. This is set against the backdrop of a one-year underperformance relative to the US Pharmaceuticals industry's 7% decline. Looking forward, these announcements could positively influence earnings forecasts, especially with expected boosts from TREMFYA and RYBREVANT within the Innovative Medicine segment. This aligns with strategic acquisitions and product launches that have been projected to grow revenue and expand market footprint. Despite these gains, competition and economic pressures remain considerations, particularly in international markets like China. Currently trading at US$150, the share price reflects a modest discount to the analyst consensus price target of US$171.11. This implies potential upside and suggests market expectations are still reconciling with Johnson & Johnson's future growth prospects. Revenue and earnings forecasts will likely incorporate these developments, while still being mindful of existing risks such as biosimilar competition and macroeconomic pressures. Review our historical performance report to gain insights into Johnson & Johnson's track record.  This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:JNJ. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com Johnson & Johnson forecasts about $400 million in costs this year related to tariffs on medical devices, said Chief Financial Officer Joseph Wolk in an interview.  Wolk said the estimated costs represent a "worst-case scenario" and take into account President Trump’s 90-day pause, China's retaliatory tariffs and the resumption of the U.S. tariffs.  J&J isn't doing anything differently yet in response to tariffs, Wolk added. Let's explore why Phillip Morris International (NYSE: PM) and Alpine Income Property Trust (NYSE: PINE) could be long-term winners.  Because nicotine is habit-forming, demand for cigarettes and other tobacco products typically remains strong no matter what is happening in the economy.  Philip Morris International has tackled this challenge through geographic diversification and a pivot to safer, reduced-risk tobacco products. We recently published a list of Jim Cramer’s Game Plan: 15 Stocks to Watch. In this article, we are going to take a look at where Bank of America Corporation (NYSE:BAC) stands against other stocks that Jim Cramer discusses. On Friday, Mad Money host Jim Cramer outlined what investors should focus on in the week, […] Want to be a better investor? Follow these strategies used by Warren Buffett Recessions are a natural part of the economic cycle, but they can have severe negative consequences for your savings and finances. To minimize its impact on your life, take these steps to recession-proof your savings. Is it possible to find savings accounts with interest rates of 4% or more? See which banks currently offer 4% interest savings accounts and open an account today. Financial advisors assist you in achieving your financial goals. If you’re making $275,000 a year, you can't contribute to a Roth IRA due to income limits. However, a backdoor conversion can allow a high earner to sock away unlimited sums in a Roth account, enabling tax-free requirement withdrawals and a way past pesky required minimum distribution rules (RMDs) that many pretax retirement account require. […] The post I’m Earning $275k This Year. Can I Use a Backdoor Roth Strategy to Reduce Taxes? appeared first on SmartReads by SmartAsset. Here are our top picks for the best online brokers for bonds. Here’s how inheriting an annuity works and what to do with it. Tip: Try a valid symbol or a specific company name for relevant results Sign in to access your portfolio 


Try again.